Accessibility Tools

Medication Legend

℞: Medications that treat viral infections and tumors are marked with the "℞" symbol.
+: Medications that contain proteins for weight gain are marked with the "+" symbol.
++: Regenerative medications for neurogenesis are marked with the "++" symbol.

Concept drawing of smallpox. Credit: Shutterstock
Concept drawing of vaccinia. Credit: Shutterstock

Bavarian Nordic announced on Feb. 6 the results of a successful Phase 3 clinical trial led by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) that demonstrated the safety and efficacy of the company’s investigational, non-replicating smallpox vaccine, IMVAMUNE®.

The product is being developed as an alternative to the current U.S. licensed replicating smallpox vaccine, ACAM2000®, which cannot be used by certain populations, including people with atopic dermatitis and HIV. It is already approved in Canada and the European Union.

USAMRIID study director Phillip R. Pittman, M.D., collaborated with the U.S. Defense Health Agency to enroll 440 subjects at a U.S. military post in South Korea. The randomized, open-label study had two co-primary endpoints. The first was to show that IMVAMUNE induced a non-inferior antibody response when compared with ACAM2000. In this study, the peak neutralizing antibodies induced by IMVAMUNE were shown to be twofold higher than those stimulated by ACAM2000, demonstrating a statistically superior immune response.

The second co-primary endpoint was to demonstrate an attenuation or prevention of a “take” in volunteers previously vaccinated with IMVAMUNE. Historically, a take is a measure of efficacy against smallpox in people vaccinated for the first time. It consisted of a pustule, scab and scar that developed on the skin following initial vaccination with replicating smallpox vaccines like ACAM2000. Following the second vaccination, those who had developed a protective immune response showed either a reduced take or none at all. This also was achieved in the USAMRIID-Bavarian Nordic study.

“If approved, this vaccine will have a direct impact on improving force health protection for U.S. Soldiers and other service members who are required to be immunized against smallpox,” said COL Gary Wheeler, commander of USAMRIID.

According to Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic, IMVAMUNE has been given to more than 7,800 subjects in 21 clinical studies, including this trial and one other Phase 3 study. He said the company plans to file a Biological License Application with the U.S. Food and Drug Administration later this year.

“This program has only been possible through the consistent and strong support of numerous U.S. Government agencies and demonstrates what can be achieved through a successful public-private partnership to protect the public from the deliberate release of the smallpox virus,” Chaplin added.

Funding for the study was provided by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100200700034C. Study details are available at https://clinicaltrials.gov/ct2/show/NCT01913353.

Content Original Link:

https://globalbiodefense.com/2018/02/19/usamriid-leads-successful-smallpox-vaccine-study/

Access Non-GMO, antigen-free, FDA-approved antiviral medication formulas used in Moderna's Spikevax.

VirusTC is a retail provider of concentrated FDA-approved antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA-approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.